Artiva Biotherapeutics is advancing a pipeline of off-the-shelf, allogeneic Natural Kill (NK) cell therapeutics for the treatment of hematologic malignancies or solid tumors. NK cells are part of the innate immune system and are the body’s natural, first line of defense against tumor cells and infection. Allogeneic NK cells are seen to be highly effective anti-cancer therapies without the significant safety risk associated with approved autologous T cell therapy (CART). To date, challenges with scaled production and cryopreservation have limited NK cell therapeutic applications.
The Artiva platform NK cells are generated from healthy donor umbilical cord blood (UCB) units selected for key characteristics. Our proprietary, large-scale, campaign-based manufacturing procedure is capable of producing enough pure and highly active NK cells to treat 100s-1000s of patients from each UCB. The pure NK cells are cryopreserved and ready for off-the-shelf therapeutic use, without the requirement for complex manipulation at the clinical site.
Our pipeline of therapeutics utilize proprietary Chimeric Antigen Receptors (CARs), optimized for use in NK cells and/or therapeutic antibodies to further enhance therapeutic activity and specificity for tumor cells. Our current focus is specific targeting of CD20 and CD19 in B-cell Lymphomas and Her2 in various solid tumor-types. Our ongoing research includes novel CAR-NK therapies and optimizing our NK cell product’s activity and persistence through specific gene editing.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.
Information on partnering; technologies that can be incorporated into product.
Short text on pipeline ---
Lorem ipsum dolor sit amet, consectetur adipiscing elit